The results, which also showed the treatment's safety in these patients, "indicate that treatment with semaglutide is a valuable therapeutic approach in the management of patients with HFpEF and ...

CLEVELAND – A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system ...

Please provide your email address to receive an email when new articles are posted on . A novel risk model can predict stroke in patients with HF with preserved ejection fraction without atrial ...

Serial KCCQ-TSS decline emerged as the most prominent pre-event signal for sudden death, contrasting with improving symptoms ...

Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed. After 12 weeks of treatment, Kansas City Cardiomyopathy ...

Please provide your email address to receive an email when new articles are posted on . Compared with placebo, Wegovy improved HF symptoms and physical limitations in patients with obesity-related ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

A negative diastolic stress test may indicate pulmonary hypertension in patients with suspected HFpEF and unexplained dyspnea. About 1 in 5 patients with unexplained dyspnea have pulmonary ...

This new study investigated the impact of overly restrictive salt-intake guidelines on patients living with heart failure with preserved ejection fraction (HFpEF), because despite accounting for half ...

Dapagliflozin (Farxiga; AstraZeneca) eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period, the ...